Multivalent Recombinant Protein Vaccine against Coccidioidomycosis




Tarcha, Eric J.
Basrur, Venkatesha
Hung, Chiung-Yu
Gardner, Malcolm J.
Cole, Garry T.

Journal Title

Journal ISSN

Volume Title


American Society for Microbiology


Coccidioidomycosis is a human respiratory disease that is endemic to the southwestern United States and is caused by inhalation of the spores of a desert soilborne fungus. Efforts to develop a vaccine against this disease have focused on identification of T-cell-reactive antigens derived from the parasitic cell wall which can stimulate protective immunity against Coccidioides posadasii infection in mice. We previously described a productive immunoproteomic/bioinformatic approach to the discovery of vaccine candidates which makes use of the translated genome of C. posadasii and a computer-based method of scanning deduced sequences of seroreactive proteins for epitopes that are predicted to bind to human major histocompatibility (MHC) class II-restricted molecules. In this study we identified a set of putative cell wall proteins predicted to contain multiple, promiscuous MHC II binding epitopes. Three of these were expressed by Escherichia coli, combined in a vaccine, and tested for protective efficacy in C57BL/6 mice. Approximately 90% of the mice survived beyond 90 days after intranasal challenge, and the majority cleared the pathogen. We suggest that the multicomponent vaccine stimulates a broader range of T-cell clones than the single recombinant protein vaccines and thereby may be capable of inducing protection in an immunologically heterogeneous human population.



Coccidioidomycosis, Coccidioides posadasii, Coccidioides, vaccine


Tarcha, E. J., Basrur, V., Hung, C.-Y., Gardner, M. J., & Cole, G. T. (2006). Multivalent Recombinant Protein Vaccine against Coccidioidomycosis. Infection and Immunity, 74(10), 5802-5813. doi:10.1128/iai.00961-06


Molecular Microbiology and Immunology